Cannabis Law Report

SEPTEMBER 1, 2021

–(BUSINESS WIRE)–Brown-Forman Corporation (NYSE: BFA, BFB) reported financial results for its first quarter of fiscal 2022 with net sales of $906 million increasing 20% 1 (+18% on an underlying basis 2 ) compared to the same prior-year period. First Quarter of Fiscal 2022 Highlights. LOUISVILLE, Ky.–(BUSINESS

Supply Chain 104

Supply Chain Business Retail Consumption 104

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: [link] Accessed October 17, 2022. February 2, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Veriheal

DECEMBER 6, 2021

Back in 2018, San Francisco voters approved a 1-5% cannabis business tax slated to go into effect early 2022. Early last week, San Francisco supervisors unanimously voted to suspend the cannabis tax through December 2022. Recent data from the California Legislative Analyst Office backs Mandelman’s claim. And he’s right!

Data 98

Data Retail Business Legislation 98

Veriheal

APRIL 11, 2024

Medical cannabis is more popular than ever before, with 38 states having legalized some form of it for various health conditions. million patients in 2022, a sharp increase from the 3.1 million patients in 2022, a sharp increase from the 3.1 This data aligns with Americans’ rising acceptance of cannabis.

Patients 111

Patients Chronic Pain Marijuana Conditions 111

Veriheal

JULY 25, 2023

A recent Quest Diagnostics Drug Testing Index Analysis revealed that positive post-accident drug tests of workers reached an all-time high in 2022. Quest Diagnostics started analyzing yearly workplace drug testing data 25 years ago in 1988, and the result of their recent study was published on May 18. Based on the report, 7.3%

Safety 95

Safety Data Recreational Marijuana 95

LifeCannMD

JANUARY 2, 2024

Medical Marijuana use has shown potential benefits in managing symptoms and improving the quality of life for individuals with various health conditions. This is the reason every Medical Marijuana state lists HIV/AIDS as one of their qualifying medical conditions.

Conditions 52

Conditions Nerve Pain Marijuana Epilepsy 52

Cannabis Law Report

MAY 1, 2022

A new report by New Frontier Data estimated that U.S. legal and illicit cannabis consumer spending reached an estimated US$97 billion in 2021, according to a new report by New Frontier Data. Cannabis is no longer a one-size-fits-all industry,” Gary Allen, CEO of New Frontier Data, said in a statement.

Data 52

Data Legalization Consumption Collective 52

Veriheal

NOVEMBER 21, 2023

As we reflect on the success of the 2022 recipients, we are thrilled to introduce the exceptional winners of the 2023 scholarship. To alleviate this burden, we awarded $5,000 scholarships to five outstanding individuals in 2022. Veriheal recognizes the financial challenges students face in pursuing higher education.

Research and Development 110

Research and Development Consumption Education Data 110

Cannabis Law Report

AUGUST 20, 2022

Press Release – Friday, August 19, 2022. CHICAGO — Governor JB Pritzker and the Illinois Department of Financial and Professional Regulation (IDFPR) today issued three additional Conditional Adult Use Dispensing Organization Licenses to applicants selected in lotteries held in the summer of 2021.

Conditions 52

Conditions Dispensary Programs Business 52

Veriheal

FEBRUARY 9, 2023

The data collected so far by the Turner Institute for Brain and Mental Health at Monash University in Australia suggests that psilocybin not only makes the process more comfortable but, as one participant described, MRIs become “magical.” All imaging and behavioral data will be accessible to the public after the study is complete.

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Veriheal

APRIL 23, 2024

By engaging individuals across various age groups and demographics, we gather insights into usage patterns, medical conditions, past substance experiences, and more. We have also used some information provided by New Frontier Data in 2022, which referenced various studies and findings on this age demographic’s substance use.

Chronic Pain 111

Chronic Pain Data Edibles Sleep 111

LifeCannMD

MAY 27, 2025

Sleep: What the Sleep Studies Reveal A groundbreaking 2020 study from the University of New Mexico analyzed sleep data from over 5,000 medical marijuana patients. A 2022 meta-analysis of 23 studies published in Clinical Pharmacology & Therapeutics found that therapeutic effects plateau at relatively low doses for most conditions.

Microdosing 52

Microdosing Research and Development Sleep Chronic Pain 52

TheAnswerPage

JULY 10, 2022

What was the second most common condition for medical cannabis licensure through 2016? PTSD was not the second most common condition for medical licensure in 2016. According to an analysis of data from U.S. Epub 14 June 2022]. In 2020, PTSD was the second most common for medical cannabis licensure. Haffajee, et al; U.S.

Chronic Pain 40

Chronic Pain Conditions Data Patients 40

Cannabis Law Report

SEPTEMBER 21, 2022

Reiterates Adjusted EBITDA Profitability Run Rate by December 31, 2022. Reaffirms $150 to $170 Million in Annualized Cost Savings by December 31, 2022. Million in Q4 2022. 20, 2022 /PRNewswire/ – Aurora Cannabis Inc. (the of Aurora’s Q4 2022 consolidated net revenue 1 and 86.3%

Research and Development 52

Research and Development Cannabis Data Programs 52

Cannabis Law Report

AUGUST 27, 2021

The Rules will be effective until at least August 19, 2022. New applicants may apply for either a conditional license or an annual license. Conditional license applications are prioritized over annual license applications to prioritize small business ownership. There are two types of fees: application fees and license fees.

Cultivation 105

Cultivation Conditions Business Cannabis 105

TheAnswerPage

JUNE 9, 2022

What is the most common qualifying condition reported by medical marijuana patients? Currently and historically the most common qualifying condition reported by medical marijuana patients is chronic pain. Qualifying Conditions of medical cannabis license holders in the United States. See the Answer.

Chronic Pain 45

Chronic Pain Conditions Data Patients 45

TheAnswerPage

MARCH 3, 2022

What is the most common qualifying condition reported by medical marijuana patients? Currently and historically the most common qualifying condition reported by medical marijuana patients is chronic pain. Qualifying Conditions of medical cannabis license holders in the United States. See the Answer.

Chronic Pain 45

Chronic Pain Conditions Data Patients 45

Veriheal

AUGUST 23, 2023

Over the span of a month, the participants were closely monitored, providing a total of 192 observations to form a robust data set. In June 2022, a study offered compelling evidence that taking microdoses of psilocybin mushrooms had a beneficial impact on mood.

Microdosing 98

Microdosing Data Treatment Conditions 98

Veriheal

JANUARY 26, 2023

Bipolar disorder is a complex condition that impacts millions worldwide, leading to extreme mood swings, intense emotional episodes, and difficulty managing day-to-day life. Further exploration of this possibility is underway to provide better care and more effective therapies for individuals living with the condition.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

Cannabis Law Report

NOVEMBER 12, 2021

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. Condensed Balance Sheet Data. . .

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

MARCH 8, 2022

DENVER) March 8, 2022 – Simplifya (“Simplifya” or “the Company”), the leading regulatory and operational compliance software platform serving the cannabis industry, announced the launch of its comprehensive suite of compliance solutions in New Mexico, expanding the company’s reach to 24 states.

Compliance 98

Compliance Compliance Research and Development Business 98

Veriheal

DECEMBER 27, 2022

Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. The subjective nature of self-reported data can plague research. Psychedelics can also cause hallucinations, out-of-body experiences, and other changes in perception.

Research and Development 102

Research and Development Therapy Consumption DEA 102

Cannabis Law Report

DECEMBER 21, 2021

Also in November, it reported positive data on its standout IND, CYB003. It’s also initiating phase 2a clinical trial into conditions such as eating disorders and fibromyalgia. 10 Psychedelic Companies To Watch In 2022. Small Pharma (CVE: DMT ) (OTCMKTS: DMTTF ). Since then, the company has also listed on the OTCQB.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

The Cannigma

AUGUST 5, 2022

A 2022 study of 22 patients with treatment-resistant depression found a 42% reduction in depressive symptoms with ketamine infusions. Most existing research does not support the use of THC in combating depression and there is very limited data for other cannabinoids.” Depression and psychedelics.

Treatment 141

Treatment Research and Development Therapy Digestion 141

Veriheal

DECEMBER 23, 2022

Dr. Maxwell’s team also collected data contained in samples sourced from California. After a close analysis of the data, the team determined that an absence of consistent federal guidelines regarding marijuana contaminants ultimately increases the risk of consumers developing health issues. 74 solvents. 21 microbes.

Research and Development 96

Research and Development Agriculture Data Extraction 96

Cannabis Law Report

AUGUST 16, 2022

August 16, 2022. The New York State Cannabis Control Board (“CCB”) approved 15 Adult-Use Conditional Processor (“AUCP”) licenses during its public meeting today, adding a key link in the state’s budding adult-use cannabis supply chain. The application window opened on June 28, 2022 and closes on August 31, 2022.

Supply Chain 52

Supply Chain Conditions Cannabinoids Cultivation 52

Veriheal

OCTOBER 3, 2022

With the growing acceptance and legalization of cannabis, the pharmaceutical industry is taking serious hits, according to a 2022 novel study into the impact of cannabis legalization on pharmaceutical firms. The team that conducted the study looked at stock return and prescription drug sales data for 556 pharmaceutical companies.

Pharmaceutical 105

Pharmaceutical Patients Research and Development Legalization 105

Cannabis Law Report

JUNE 1, 2021

Remains on track to achieve positive Adjusted EBITDA during the second half of FY 2022. opportunities in Fiscal 2022.” In Q1 2022, Canopy has expanded its portfolio of THC beverages with Tweed Iced Tea beverages (available in lemon and raspberry flavors, both with 5 mg THC) now shipping. Net revenue. Adjusted EBITDA 3.

Data 95

Data Vaping Supply Chain Business 95

Veriheal

JUNE 19, 2023

As of 2022, the global psychedelics market was valued at $4.87 All the data provided by the report are validated and trustworthy and can be used to gain the upper hand in the industry. Psilocybin is useful in treating depression and anxiety, especially when the mental health condition is related to life-threatening illnesses.

Therapy 111

Therapy Treatment Patients Policy 111

Illinois News Joint

FEBRUARY 7, 2023

The Disparity and Availability Study’s purpose is to collect and analyze data and will report on whether discrimination exists in the Illinois cannabis industry. On February 14, 2022, the State published a formal request for proposals (RFP) to find a vendor to conduct a Disparity Study of the cannabis licensing system. Constitution.

Agriculture 98

Agriculture Cannabis Policy Dispensary 98

Cannabis Law Report

SEPTEMBER 7, 2022

Since the legalisation of medical cannabis in the UK in 2018, there is little education surrounding medical cannabis and how it can help a large variety of conditions, should traditional medicine leave patients with an ‘unmet clinical need.’ . Cantourage Clinic is a leading medical cannabis clinic in the UK with a difference. .

Patients 52

Patients Conditions Treatment Education 52

Veriheal

SEPTEMBER 14, 2021

While the pool of study subjects could have been larger, researchers were satisfied with the data they gathered from 3,119 respondents. All respondents identified as American military veterans, and the information was pulled from a 2012–2013 National Epidemiologic Survey on Alcohol and Related Conditions–III (NESARC-III). .

Consumption 98

Consumption Research and Development Treatment Programs 98

Cannabis Law Report

NOVEMBER 29, 2021

As we approach the 2022 legislative session and the elections next November, it is important for lawmakers of all political persuasions to recognize that advocating for marijuana policy reforms is a political opportunity, not a political liability,” NORML’s Paul Armentano said. The law will take effect in January 2022. California.

Legislation 98

Legislation Patients Retail Law 98

Cannabis Law Report

APRIL 14, 2022

Local governments may also impose zoning conditions on cannabis facilities, including but not limited to buffer zones, density conditions, hours of operation, odor control requirements, necessary operating permits, and storefront characteristics. Next Steps.

Environment 52

Environment Agriculture Compliance Compliance 52

Cannabis Law Report

JULY 25, 2022

The data from this study is currently being assembled and MindBio is set to further announce the new findings. — MindBio Therapeutics (@MindBioTherap) July 10, 2022. together with research collaborators at the University of Auckland , have received NZ$1.44

Microdosing 52

Microdosing Clinical Trials Research and Development Data 52

Cannabis Law Report

AUGUST 23, 2021

Analysts predict that pet-and-animal product sales are among the fastest-growing sectors in the CBD market with estimated sales reaching $125 million by 2022. He added that significant data is still needed to inform policy regarding use of consumer cannabis products. WRITTEN BY: Womble Bond Dickinson. Heather Hatcher, Ph.D.

Pets 105

Pets Hemp CBD Food 105

Veriheal

MAY 17, 2022

The danger of exposure to fine particulate matter lies in the fact that these particles are able to “travel deeply into the respiratory tract, reaching the lungs,” which can then cause lung irritation, coughing, sneezing, shortness of breath, worsening lung function, and even worsening conditions such as asthma and heart disease.

Concentrates 98

Concentrates Data Conditions Cannabis 98